Purolite Life Sciences | Reflecting on 2018

As we move ever closer to the end of another successful year, the team at Purolite Life Sciences would like to wish you a happy and prosperous 2019.

2018 was Purolite Life Sciences' most successful year to date, with huge strides taken to continue to deliver our vision of bringing innovative thinking and technological expertise to our customers. For this, we would like to thank all of our partners, collaborators and customers for their contributions and support throughout the year, and we look forward to working with you in 2019.

From successfully opening our new state of the art 100,000L Agarose Manufacturing Facility in Llantrisant, to expanding our solutions portfolio and our team, 2018 was certainly an exciting year. As ever, we look forward to continued growth in 2019, to provide the most innovative, effective customer solutions in the industry. 

See some of our 2018 highlights below...

Purolite officially opens one of the world's largest agarose resin manufacturing facilities

Officially opened on September 27th by the Rt Hon Carwyn Jones AM, First Minister of Wales, and Steve Bates, CEO of the BioIndustry Association, our state-of-the-art agarose resin manufacturing facility in Llantrisant, is capable of producing 100,000L annually – equating to 30% of current global demand.  The new manufacturing facility will enable dual-sourcing of agarose resins to secure a consistent supply. Spread over 2400 sq. m, the purpose-built facility leverages Purolite’s manufacturing knowledge to optimize for lower energy, less raw material consumption and more time efficient processes. It is predicted that the South Wales-based facility will promote increased resin innovation within the field, reducing the end-user cost of biologics and boosting local supply chains by up to £120 million. Read more >>

It's been a busy year, and we've been in attendance at exhibitions and conferences around the globe - from Biotech Week in Boston, to CPhI Worldwide in Madrid and recently the bioProcess UK conference in Edinburgh.

Our portfolio of products has expanded in 2018...

This summer we received encouraging news that our Praesto® resins reached Phase III clinical trials, having been used for the purification of several innovative therapies. We have also experienced strong success in the biosimilar space too.  Although our Praesto resins technology has only commercially been available for around two years, reaching this late stage in clinical trials is an endorsement of both their strong performance and value in the field of monoclonal antibody purification.  We are proud that our resin technology has made such a forceful impact in a relatively short space of time in the field of biopharmaceutical development. 

Praesto® Jetted A50

is the only bioprocess scale agarose resin available with a uniform particle size distribution. Designed to meet the future demands in mAb processing Praesto® Jetted A50 addresses the increased titres from today’s bioreactors, and allows customers to increase productivity from the same manufacturing footprint. Read more >>

PuroSynth™

supports for Solid Phase Peptide Synthesis (SPPS) are made of polystyrene containing 1% divinylbenzene (DVB) as a crosslinking agent. This polystyrene resin is insoluble in all common solvents, it swells well in most organic solvents and is supplied as uniform spherical beads.  Read more >>

Chromalite® M

products based on methacrylate, are an excellent alternatives to Tosoh resins for optimal downstream purification of peptides, oligonucleotides, proteins, enzymes and biomolecules up to 500kDa in size.  With a variety of particle sizes to suit your process, Chromalite® M resins are an ideal choice for high resolution, intermediate or capture chromatography from lab to commercial-scale.  Read more >>

Wishing you a very Happy Christmas and a prosperous New Year.